CorMedix Inc Stock News

Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and specialty pharmaceuticals industry Joseph Todi

Gainers Marygold Companies (NYSE: MGLD ) jumped 189.4% to $6.28 after dropping 21% on Thursday. Altamira Therapeutics Ltd. (NASDAQ: CYTO ) shares rose 63.5% to $1.13. Altamira Therapeutics reported in vitro efficacy data for bentrio nasal spray in protecting against Sars-CoV-2 omicron variant. Excellon Resources Inc. (NYSE: EXN ) rose 40.7% to $1.38 after jumping around 13% on Thursday. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 35.5% to $1.8301 after the company reported better-than-expected Q4 results. Alset EHome International Inc. (NASDAQ: AEI ) shares rose 31% to $ 0.4555 after dropping 7% on Thursday. Humanigen, Inc. (NASDAQ: HGEN ) jumped 22.7% to $3.44. Lazydays Holdings, Inc. (NASDAQ: LAZY ) gained 22% to $21.80 after the company reported Q4 earnings results. Blue Star Foods Corp. (NASDAQ: BSFC ) jumped 19.8% to $2.54. 4D pharma plc (NASDAQ: LBPS ) shares climbed 19.7% to $3.53. Paramount Gold Nevada Corp. (NYSE: PZG ) rose 19% to $0.9404 after jumping 14% on Thursday. Pearson plc (NYSE: PSO ) gained 19% to $10.35.

Puma Biotech (PBYI) delivered earnings and revenue surprises of 190.91% and 16.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -20.29% and 14.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

CorMedix Inc (NASDAQ: CRMD ) has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the FDA. In parallel, the Company''s third-party manufacturer submitted responses to the deficiencies identified at the manufacturing facility in the Post-Application Action Letter issued by the FDA concurrently with the CRL. In March last … Full story available on Benzinga.com

BERKELEY HEIGHTS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention

BERKELEY HEIGHTS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD ), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) a year ago. In parallel, the Company''s third-party manufacturer submitted responses to the deficiencies identified at the manufacturing facility in the Post-Application Action Letter ("PAAL") issued by the FDA concurrently with the CRL. DefenCath is being developed as a catheter lock solution with an initial indication of use for the reduction of catheter-related bloodstream infections (CRBSIs) in patients with renal failure who are receiving chronic hemodialysis via a central venous catheter. The FDA has 30 days to review the submission for completeness to accept for filing and provide guidance on the review timeline.

Spire Wealth Management increased its holdings in shares of CorMedix Inc. (NYSEAMERICAN:CRMD) by 166.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,200 shares of the biotechnology companys stock after buying an additional 7,000 shares during the period. Spire Wealth []

State Street Corp cut its stake in CorMedix Inc. (NYSEAMERICAN:CRMD) by 5.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 630,654 shares of the biotechnology companys stock after selling 35,957 shares during the period. State Street Corps holdings in []

CorMedix Inc. (NYSEAMERICAN:CRMD) Director Myron Kaplan purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, November 16th. The stock was bought at an average price of $5.14 per share, with a total value of $51,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available []

Zacks Investment Research downgraded shares of CorMedix (NYSEAMERICAN:CRMD) from a hold rating to a sell rating in a research report report published on Friday morning, Zacks.com reports. According to Zacks, CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company []

CorMedix Inc. (NYSEAMERICAN:CRMD) Equities research analysts at Truist Securiti decreased their FY2021 earnings estimates for CorMedix in a research report issued on Tuesday, November 9th. Truist Securiti analyst J. Lee now anticipates that the biotechnology company will post earnings of ($0.76) per share for the year, down from their prior forecast of ($0.69). Truist []

CorMedix (CRMD) delivered earnings and revenue surprises of -22.22% and 280.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix Inc. (CRMD) CEO Matt David on Q3 2021 Earnings Call Transcript